Meeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4504 Authors: Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, et. al. Background: Patients (pts) with mUC are in need of novel therapies. Enfortumab vedotin (EV) is an antibody–drug conjugate that delivers a microtubule-disrupting agent to tumors expressing Nectin-4, a protein overexpressed...
Pro zobrazení tohoto obsahu je třeba být přihlášen.